{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:35:20Z","timestamp":1760056520990,"version":"build-2065373602"},"reference-count":102,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007683","name":"Nihon University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ccl.2021.04.012","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T22:14:13Z","timestamp":1625782453000},"page":"415-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Rajesh","family":"Mohandas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gajapathiraju","family":"Chamarthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ccl.2021.04.012_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197403282901301","article-title":"Accelerated atherosclerosis in prolonged maintenance hemodialysis","volume":"290","author":"Lindner","year":"1974","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2011.02.017","article-title":"Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease\u2013a cross-sectional study of predialysis, dialysis and kidney-transplantation patients","volume":"216","author":"Recio-Mayoral","year":"2011","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.012_bib3","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2215\/CJN.12811216","article-title":"Endothelium-dependent and -independent vascular function in advanced chronic kidney disease","volume":"12","author":"Kopel","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.012_bib4","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1681\/ASN.2005020179","article-title":"Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study","volume":"16","author":"Fliser","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/path.2769","article-title":"Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-beta1 synthesis","volume":"223","author":"Mihout","year":"2011","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2215\/CJN.05340610","article-title":"Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress","volume":"6","author":"Yu","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24\u201326","key":"10.1016\/j.ccl.2021.04.012_bib7","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.lfs.2013.05.008","article-title":"Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats","volume":"92","author":"Yisireyili","year":"2013","journal-title":"Life Sci"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.012_bib8","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2010020143","article-title":"The NLRP3 inflammasome promotes renal inflammation and contributes to CKD","volume":"21","author":"Vilaysane","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.012_bib9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archinte.167.12.1262","volume":"167","author":"Nanayakkara","year":"2007","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.012_bib10","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2014010042","article-title":"Randomized placebo-controlled EPPIC trials of AST-120 in CKD","volume":"26","author":"Schulman","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.ccl.2021.04.012_bib11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2369-14-132","article-title":"Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001\u20132010","volume":"14","author":"Kuznik","year":"2013","journal-title":"BMC Nephrol"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","article-title":"Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) Study","volume":"55","author":"Muntner","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.012_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2215\/CJN.12551117","article-title":"BP measurement techniques","volume":"13","author":"Thomas","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.117.08314","article-title":"Hypertensive kidney injury and the progression of chronic kidney disease","volume":"70","author":"Griffin","year":"2017","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/j.ackd.2014.12.001","article-title":"Management of hypertension in CKD: beyond the guidelines","volume":"22","author":"Judd","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1161\/01.HYP.0000145180.38707.84","article-title":"Pathophysiology of hypertensive renal damage","volume":"44","author":"Bidani","year":"2004","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib18","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system","volume":"292","author":"Mehta","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000345243","article-title":"Vascular actions of aldosterone","volume":"50","author":"Briet","year":"2013","journal-title":"J\u00a0Vasc Res"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.012_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nrneph.2015.114","article-title":"Management of hypertension in chronic kidney disease","volume":"11","author":"Townsend","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1523-1755.2004.00552.x","article-title":"Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment","volume":"65","author":"Neumann","year":"2004","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jama.2019.9811","article-title":"Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes","volume":"322","author":"Yang","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05391008","article-title":"Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis","volume":"4","author":"Bangash","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.012_bib24","doi-asserted-by":"crossref","first-page":"e011013","DOI":"10.1161\/JAHA.118.011013","article-title":"Magnitude of the difference between clinic and ambulatory blood pressures and risk of adverse outcomes in patients with chronic kidney disease","volume":"8","author":"Ku","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.012_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11886-019-1154-4","article-title":"Masked hypertension in CKD: increased prevalence and risk for cardiovascular and renal events","volume":"21","author":"Babu","year":"2019","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib26","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.115.06896","article-title":"Hypertension in chronic kidney disease part 2","volume":"67","author":"Parati","year":"2016","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib27","doi-asserted-by":"crossref","first-page":"642","DOI":"10.2215\/CJN.08530815","article-title":"Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.012_bib29","first-page":"e484","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"issue":"9889","key":"10.1016\/j.ccl.2021.04.012_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"13","key":"10.1016\/j.ccl.2021.04.012_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ccl.2021.04.012_bib33","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease<SUBTITLE>Results from the AASK trial<\/SUBTITLE>","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"9463","key":"10.1016\/j.ccl.2021.04.012_bib34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.012_bib35","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa0910975","article-title":"Intensive blood-pressure control in hypertensive chronic kidney disease","volume":"363","author":"Appel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.012_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upadhyay","year":"2011","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.ccl.2021.04.012_bib37","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.012_bib38","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000446122","article-title":"Cardiovascular outcomes in action to control cardiovascular risk in diabetes: impact of blood pressure level and presence of kidney disease","volume":"43","author":"Papademetriou","year":"2016","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib40","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.119.12697","article-title":"Mortality outcomes with intensive blood pressure targets in chronic kidney disease patients","volume":"73","author":"Aggarwal","year":"2019","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.012_bib41","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD","volume":"23","author":"Vegter","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.012_bib43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.012_bib44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9638","key":"10.1016\/j.ccl.2021.04.012_bib46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib47","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0272-6386(96)90363-7","article-title":"Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients","volume":"27","author":"Braun","year":"1996","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.CIR.0000020222.63035.C0","article-title":"Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure","volume":"106","author":"Oh","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1681\/ASN.2007070765","article-title":"Association of mild to moderate kidney dysfunction and coronary calcification","volume":"19","author":"Ix","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2215\/CJN.05120610","article-title":"Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the calcification outcome in renal disease (CORD) study","volume":"6","author":"Verbeke","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"20","key":"10.1016\/j.ccl.2021.04.012_bib51","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","article-title":"Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis","volume":"342","author":"Goodman","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.012_bib52","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1161\/01.RES.87.7.e10","article-title":"Phosphate regulation of vascular smooth muscle cell calcification","volume":"87","author":"Jono","year":"2000","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib53","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1046\/j.1523-1755.2002.00170.x","article-title":"Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins","volume":"61","author":"Moe","year":"2002","journal-title":"Kidney Int"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.012_bib54","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.108.783738","article-title":"Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis","volume":"118","author":"Shroff","year":"2008","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.ccl.2021.04.012_bib55","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/CIRCULATIONAHA.112.000571","article-title":"Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment","volume":"127","author":"Villa-Bellosta","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.04.012_bib56","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fcvm.2018.00196","article-title":"Endogenous calcification inhibitors in the prevention of vascular calcification: a consensus statement from the COST action EuroSoftCalcNet","volume":"5","author":"Back","year":"2018","journal-title":"Front Cardiovasc Med"},{"issue":"113","key":"10.1016\/j.ccl.2021.04.012_bib57","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.012_bib59","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s11255-014-0751-9","article-title":"Magnesium retards the progress of the arterial calcifications in hemodialysis patients: a pilot study","volume":"46","author":"Tzanakis","year":"2014","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.012_bib60","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s11255-019-02275-2","article-title":"The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial","volume":"51","author":"Oikonomaki","year":"2019","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.012_bib61","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.119.044195","article-title":"Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized phase 2b study","volume":"141","author":"Raggi","year":"2020","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.012_bib62","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.012_bib63","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1681\/ASN.2020040411","article-title":"A\u00a0randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD)","volume":"31","author":"Toussaint","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9784","key":"10.1016\/j.ccl.2021.04.012_bib64","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ccl.2021.04.012_bib65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijcard.2015.02.072","article-title":"High dose and long-term statin therapy accelerate coronary artery calcification","volume":"184","author":"Henein","year":"2015","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.atherosclerosis.2012.08.002","article-title":"Statins use and coronary artery plaque composition: results from the International Multicenter CONFIRM Registry","volume":"225","author":"Nakazato","year":"2012","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib67","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2215\/CJN.00530108","article-title":"Calciphylaxis from nonuremic causes: a systematic review","volume":"3","author":"Nigwekar","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.012_bib68","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1681\/ASN.2015091065","article-title":"A\u00a0nationally representative study of calcific uremic arteriolopathy risk factors","volume":"27","author":"Nigwekar","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib69","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1523-1755.2001.00803.x","article-title":"Risk factors and mortality associated with calciphylaxis in end-stage renal disease","volume":"60","author":"Mazhar","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000371449","article-title":"Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease","volume":"129","author":"Galloway","year":"2015","journal-title":"Nephron"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib71","first-page":"126","article-title":"Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry","volume":"32","author":"Brandenburg","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib72","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000348806","article-title":"Statin use and calcific uremic arteriolopathy: a matched case-control study","volume":"37","author":"Nigwekar","year":"2013","journal-title":"Am J Nephrol"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.012_bib73","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib74","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000491881","article-title":"The successful use of apixaban in dialysis patients with calciphylaxis who require anticoagulation: a retrospective analysis","volume":"48","author":"Garza-Mayers","year":"2018","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib75","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/ki.2012.191","article-title":"Vitamin K intake and status are low in hemodialysis patients","volume":"82","author":"Cranenburg","year":"2012","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamadermatol.2015.4591","article-title":"The role of bone scintigraphy in the diagnosis of calciphylaxis","volume":"153","author":"Paul","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib77","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4103\/1450-1147.203076","article-title":"The role of bone scintigraphy with single-photon emission computed tomography-computed tomography in the diagnosis and evaluation of calciphylaxis","volume":"16","author":"Martineau","year":"2017","journal-title":"World J Nucl Med"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.012_bib78","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.09880912","article-title":"Sodium thiosulfate therapy for calcific uremic arteriolopathy","volume":"8","author":"Nigwekar","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"year":"2020","series-title":"Phase 2 trial of phytonadione in calciphylaxis","author":"Nigwekar","key":"10.1016\/j.ccl.2021.04.012_bib79"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib80","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.amjcard.2007.04.045","article-title":"Predictors of survival in patients with end-stage renal disease evaluated for kidney transplantation","volume":"100","author":"Hage","year":"2007","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.012_bib81","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/j.1600-6143.2008.02281.x","article-title":"Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study","volume":"8","author":"Patel","year":"2008","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib82","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jcmg.2017.07.012","article-title":"Prognostic value of risk factors, calcium score, coronary CTA, myocardial perfusion imaging, and invasive coronary angiography in kidney transplantation candidates","volume":"11","author":"Winther","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.012_bib83","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1915925","article-title":"Management of coronary disease in patients with advanced kidney disease","volume":"382","author":"Bangalore","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib84","doi-asserted-by":"crossref","first-page":"e0125374","DOI":"10.1371\/journal.pone.0125374","article-title":"Renal function and coronary microvascular dysfunction in women with symptoms\/signs of ischemia","volume":"10","author":"Mohandas","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib85","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCIMAGING.110.957761","article-title":"Coronary microvascular function in early chronic kidney disease","volume":"3","author":"Charytan","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.012_bib86","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.ki.5000031","article-title":"Mild renal insufficiency is associated with reduced coronary flow in patients with non-obstructive coronary artery disease","volume":"69","author":"Chade","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib87","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1681\/ASN.2015030301","article-title":"Prognostic value of coronary flow reserve in patients with dialysis-dependent ESRD","volume":"27","author":"Shah","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib88","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ahj.2003.07.029","article-title":"Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries","volume":"147","author":"Ragosta","year":"2004","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.012_bib89","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1681\/ASN.V961018","article-title":"Myocyte\/capillary mismatch in the heart of uremic patients","volume":"9","author":"Amann","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib90","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41598-018-37969-7","article-title":"Correlation of systemic arterial stiffness with changes in retinal and choroidal microvasculature in type 2 diabetes","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib91","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1681\/ASN.2014050450","article-title":"Mediation analysis of aortic stiffness and renal microvascular function","volume":"26","author":"Woodard","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.012_bib92","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMra061889","article-title":"Coronary microvascular dysfunction","volume":"356","author":"Camici","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.012_bib93","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1055\/s-0038-1672206","article-title":"Genetic depletion of thromboxane A2\/thromboxane-prostanoid receptor signalling prevents microvascular dysfunction in ischaemia\/reperfusion injury","volume":"118","author":"Chiang","year":"2018","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib94","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/01.CIR.0000100722.34034.E4","article-title":"Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: role of superoxide dismutase activity","volume":"109","author":"Pizzi","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.012_bib95","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.ATV.20.3.737","article-title":"Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries","volume":"20","author":"Hamasaki","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.012_bib96","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ahj.2011.07.011","volume":"162","author":"Pauly","year":"2011","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.ccl.2021.04.012_bib97","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jcmg.2011.03.007","article-title":"Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease","volume":"4","author":"Mehta","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib98","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.amjcard.2013.02.045","article-title":"Effects of ivabradine and ranolazine in patients with microvascular angina pectoris","volume":"112","author":"Villano","year":"2013","journal-title":"Am J Cardiol"},{"issue":"19","key":"10.1016\/j.ccl.2021.04.012_bib99","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehv647","article-title":"A\u00a0randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve","volume":"37","author":"Bairey Merz","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.012_bib100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/clc.20935","article-title":"Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study","volume":"34","author":"Denardo","year":"2011","journal-title":"Clin Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.012_bib101","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCULATIONAHA.110.967406","article-title":"Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis","volume":"122","author":"Reriani","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.012_bib102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0735-1097(02)02632-3","article-title":"Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm","volume":"41","author":"Mohri","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:53:42Z","timestamp":1760007222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865121000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0733865121000357"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2021.04.012","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonatherosclerotic Vascular Abnormalities Associated with Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2021.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}